3-Month Lag/Transition Period | 6-Month Lag/ Transition Period | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intervention: Oxycontin ADF released (2010 Q3) | Intervention: Oxycontin ADF released (2010 Q3) | ||||||||||||||||
Parameter | Estimate | P-value | AIC | Parameter | Estimate | P-value | AIC | ||||||||||
AR1 (𝜖) | 0.60 | < 0.001 | -183.7 | AR1 (𝜖) | 0.57 | < 0.001 | -185.6 | ||||||||||
Intercept (𝛽0) | 0.21 | < 0.001 | Intercept (𝛽0) | 0.17 | < 0.001 | ||||||||||||
Ramp (𝛽2) | 0.023 | < 0.001 | Ramp (𝛽2) | 0.02 | < 0.001 | ||||||||||||
Intervention: Peak dosage units (2011 Q3) | Intervention: Peak dosage units (2011 Q3) | ||||||||||||||||
Parameter | Estimate | P-value | AIC | Parameter | Estimate | P-value | AIC | ||||||||||
AR1 (𝜖) | 0.50 | < 0.001 | -188.7 | AR1 (𝜖) | 0.50 | < 0.001 | -189.4 | ||||||||||
Intercept (𝛽0) | 0.18 | < 0.001 | Intercept (𝛽0) | 0.18 | < 0.001 | ||||||||||||
Ramp (𝛽2) | 0.02 | < 0.001 | Ramp (𝛽2) | 0.02 | < 0.001 | ||||||||||||
Intervention: Peak MMEs (2012 Q4) | Intervention: Peak MMEs (2012 Q4) | ||||||||||||||||
Parameter | Estimate | P-value | AIC | Parameter | Estimate | P-value | AIC | ||||||||||
AR1 (𝜖) | 0.11 | < 0.001 | -182.9 | AR1 (𝜖) | 0.67 | < 0.001 | -180.7 | ||||||||||
Intercept (𝛽0) | 0.02 | < 0.001 | Intercept (𝛽0) | 0.21 | < 0.001 | ||||||||||||
Ramp (𝛽2) | 0.00 | < 0.001 | Ramp (𝛽2) | 0.02 | < 0.001 |